Background We assessed whether fully closed-loop insulin delivery (the so-called artifi cial pancreas) is safe and eff ective compared with standard subcutaneous insulin therapy in patients with type 2 diabetes in the general ward.
Introduction
The prevalence of hyperglycaemia in hospital inpatients is increasing and poses a common clinical problem because of the rising prevalence of type 2 diabetes. 1, 2 Inpatient hyperglycaemia is a widely recognised marker of poor prognosis and is associated with increased morbidity, mortality, length of stay, and health-care costs. 3, 4 Guidelines for management of hyperglycaemia in inpatients outside the critical care setting have been proposed, 5 but implementation is challenging and varied because of increased workload burden on ward staff and fear of hypoglycaemia. Development of eff ective and safe treatments that also reduce staff workload in the general ward is needed.
An automated system linking continuous glucose monitoring and insulin delivery could be a potential solution. 6 Closed-loop insulin delivery, known as the artifi cial pancreas, is an emerging approach in which a control algorithm autonomously increases and decreases subcutaneous insulin delivery on the basis of real-time sensor glucose concentrations, thus approximating physiological insulin delivery. 7 Studies of closed-loop insulin delivery at home in patients with type 1 diabetes have shown the safety and feasibility of the approach in improving glycaemic control and reducing the risk of hypoglycaemia. 8, 9 A closed-loop insulin delivery system has been shown to be safe and feasible in insulin-naive patients with type 2 diabetes in a controlled research facility setting. 10 We investigated the effi cacy and safety of automated closed-loop insulin de livery without meal-time boluses compared with conventional subcutaneous insulin therapy in patients with type 2 diabetes in the general ward.
Methods

Study design and participants
In this single-centre, open-label, parallel-design controlled trial, we recruited participants from general wards at Addenbrooke's Hospital, Cambridge, UK. Inclusion criteria were age 18 years or older, diagnosis of type 2 diabetes as defi ned by WHO for at least 1 year, and treatment with insulin with or without other glucose-lowering therapy. Exclusion criteria were treatment in intensive care unit, unstable or end-stage cardiac and renal disease including dialysis, pregnancy or breastfeeding, planned surgery during study period, and any physical or psychological disease or medication(s) likely to interfere with the conduct of the study or interpretation of study results. Participants provided written informed consent before the start of study-related procedures. The study protocol was approved by the East of England Central Cambridge Ethics Committee.
Randomisation and masking
Eligible participants were randomly assigned (1:1) to receive fully automated closed-loop insulin delivery or conventional insulin therapy. Randomisation was done by a minimisation method using Minim randomisation software, 11 which is a biased coin approach with a probability of 0·7-0·8 to allocating the best-fi tting treatment. Randomisation was stratifi ed according to HbA 1c , BMI, and pre-study total insulin dose to ensure balance between the two groups. Investigators analysing study data were not masked to treatment allocation.
Procedures
Participants' bodyweight, height, and total daily insulin dose were recorded after enrolment. Throughout the study, participants chose standard ward meals at usual meal times in the general ward. No restrictions were placed on consuming other meals and snacks or on usual activity in the general ward. Participants were followed up for a maximum of 72 h.
In the closed-loop insulin delivery group, participants' usual insulin therapy and sulfonylurea medication, if prescribed, were discontinued on the day of closed-loop initiation, all other anti-diabetes medications were continued. A subcutaneous cannula was inserted by the investigator in the abdomen for delivery of insulin lispro (Humalog, Eli Lilly, IN, USA) by an insulin pump (Dana R Diabecare, Sooil, Seoul, South Korea). A subcutaneous, real-time, continuous glucose monitor (Freestyle Navigator II, Abbott Diabetes Care, Alameda, CA, USA) was inserted in the abdomen or upper arm by the investigator and calibrated according to the manufacturer's instructions. After successful sensor calibration when sensor glucose concentrations became available, automated closed-loop glucose control was started by the investigator and continued for 72 h. The low glucose alarm on the continuous glucose monitoring receiver was initially set at a threshold of 3·5 mmol/L. The FlorenceD2W-T2 automated closed-loop system comprised a model predictive control algorithm (version 0.3.65) residing on a control algorithm device (Dell Latitude 10 Tablet, Dell, TX, USA) linked by a USB cable to the continuous glucose monitoring receiver (FreeStyle Navigator II). The tablet communicated with the study pump (Dana R Diabecare) via the Bluetooth wireless communication protocol.
The control algorithm was initialised with participant's bodyweight and pre-study total daily insulin dose. No prandial insulin boluses were delivered and the control algorithm was not provided with timing or carbohydrate content of meals. Every 12 min, the control algorithm calculated the required insulin infusion rate based on sensor glucose measurements. The study pump was then instructed by wireless communication to alter or maintain insulin delivery rate. The control algorithm adapted to a particular participant by updating model parameters and refi ning the individual's insulin requirements. The algorithm aimed to achieve glucose concentrations
Research in context
Evidence before this study We searched PubMed for articles published between Jan 1, 2006 and June 22, 2016, with the search terms ("closed-loop" OR "artifi cial pancreas") AND ("type 2 diabetes" OR "inpatient hyperglycaemia" OR "stress hyperglycaemia" OR ("hospital" AND "hyperglycaemia")) to identify other novel methods in the management of hyperglycaemia in inpatients. Apart from intravenous closed-loop insulin delivery in intensive care settings, no studies of fully closed-loop subcutaneous insulin delivery in the non-critical settings have been published to date.
Added value of this study
We are not aware of any other study assessing automated fully closed-loop insulin delivery without meal-time boluses in adults with insulin-treated type 2 diabetes in the non-critical care setting. Our results showed a higher proportion of time spent in the target glucose range and reduced glucose variability with closed-loop insulin delivery compared with conventional therapy, without changing the total daily insulin dose or the time spent in hypoglycaemia. Reduction in overnight mean glucose concentration by closed-loop insulin delivery was achieved without increasing the risk of nocturnal hypoglycaemia. Taken together, our fi ndings suggest that an automated closed-loop insulin delivery system can potentially provide health-care professionals with a valuable clinical tool to manage inpatient hyperglycaemia safely and eff ectively while possibly reducing workload.
Implications of all the available evidence
Guidelines for the management of hyperglycaemia in inpatients have been published, with increased focus on integrated glycaemic management systems and education of health-care providers. Data from several inpatient audits and studies show that implementation in clinical practice is challenging because of the increasing workload on staff and the accelerating increase in the prevalence of diabetes. Technology remains underused in non-critical care management of inpatient hyperglycaemia. Further studies are needed to assess the potential of closed-loop insulin delivery and other technological approaches to improve clinical outcomes including assessing the eff ect on morbidity and mortality. between 5·8 mmol/L and 7·2 mmol/L and adjusted the actual target threshold depending on accuracy of the model-based glucose predictions and prevailing glucose concentrations. Safety rules limited maximum insulin infusion rate on individual basis based on total daily dose and suspended insulin delivery at sensor glucose concentration of 4·2 mmol/L or lower, or when sensor glucose concentration was rapidly decreasing. In the event of sensor failure or loss of sensor availability, an audible alarm by the continuous glucose monitoring receiver sounded to alert the general ward staff or the research team. If sensor glucose measurements continued to be unavailable for 30 min, the study pump insulin infusion rate reverted to the individual's preprogrammed basal rate. For longer interruptions of sensor glucose measurements, the control algorithm could be provided with capillary glucose measurements to direct insulin delivery.
Once-daily subcutaneous basal insulin glargine (Sanofi , Gentilly, France), at 20% of the participant's pre-study total daily insulin dose, was proposed during risk analysis by the interdisciplinary research team to mitigate against the risk of severe hyperglycaemia associated with ketonaemia in the event of prolonged pump disconnection for specifi c clinically indicated procedures such as MRI, when insulin pump use is contraindicated. This approach was chosen because no studies of closed-loop insulin delivery had been done in this population of patients, practical information was missing within the general ward setting to inform potential safety mitigation, and the dose administered was unlikely to aff ect effi cacy outcomes. The basal insulin dose was kept constant and not titrated throughout the study period. Point-of-care capillary glucose measurements (Nova Stat Strip, Nova Biomedical, MA, USA) were taken by nursing ward staff according to usual clinical practice. These measurements were not used to inform or change insulin delivery rate. At the end of the closed-loop period, participants completed a brief questionnaire providing feedback on satisfaction of glucose control while receiving the closed-loop intervention, such as wearability and mobility with the devices, trust of the closed-loop device to deliver insulin, and whether they would recommend the closed-loop intervention to others. Participants' usual insulin therapy and, as appropriate, sulfonylurea medication was restarted at the end of the closed-loop intervention.
In the conventional insulin therapy group, participants' usual insulin and other antihyperglycaemic therapy was continued throughout the 72 h study period. A continuous glucose monitoring receiver (Freestyle Navigator II) was modifi ed to mask sensor glucose concentrations to the participant, investigators, and ward staff . The continuous glucose monitoring sensor was inserted in the general ward by the clinical investigator on the fi rst day of the study and calibrated according to the manufacturer's instructions. Point-of-care capillary glucose measurements were taken by nursing ward staff (Nova Stat Strip). Participants' glucose control was managed by the clinical team according to local clinical practice. The clinical team was allowed to modify and adjust insulin or other antihyperglycaemic therapy and instigate additional point-of-care capillary glucose measurements as appropriate.
Outcomes
The primary outcome was time spent in the target glucose concentration range of 5·6-10·0 mmol/L during the 72 h study period, as recorded by sensor glucose measurements. Secondary effi cacy outcomes were the time spent at glucose concentrations lower than 5·6 mmol/L and greater than 10·0 mmol/L, area under the curve less than 3·5 mmol/L, mean sensor glucose concentration, and total daily insulin dose. Glucose variability was assessed by the SD and the coeffi cient of variation of sensor glucose concentration using data collected from the whole study period. The between-day coeffi cient of variation of sensor glucose concentration was calculated from daily mean glucose measurements (0000-0000 h). Daytime (0800-0000 h) and overnight (0000-0800 h) outcomes were calculated for a subset of outcomes to limit multiple comparisons. These outcomes included time in the target range, time spent at concentrations greater than the target range, mean sensor glucose concentration, the SD and the coeffi cient of variation of sensor glucose concentration, the betweenday or between-night coeffi cient of variation of sensor glucose concentration, and area under the curve less than 3·5 mmol/L using data from the respective periods. The mean pre-meal and pre-bed capillary glucose concentration at each defi ned time period was calculated for each participant for the whole study period. Safety endpoints included clinically signifi cant hypoglycaemic episodes (<3·5 mmol/L) and other adverse and serious adverse events in accordance with ISO 14155 reporting.
Statistical analysis
Findings from previous studies of closed-loop insulin delivery in patients with type 1 diabetes show that time when sensor glucose concentration is in the target range (primary endpoint) has an SD of 21%. [12] [13] [14] We calculated that with 18 participants per group, a diff erence of 20% between groups could be detected with a power of 80% using two-sided unpaired t test at a 5% signifi cance level. A diff erence of 20% was deemed clinically relevant. The group size was increased to 20 to mitigate against possible diff erences between type 1 and type 2 diabetes. The statistical analysis plan was agreed by the investigators in advance. Outcomes were calculated with GStat software (version 2.2) and statistical analyses were done with SPSS (version 21). Because of the sample size, we used an unpaired t test to compare variables with the exception of highly skewed variables, when we used a Mann-Whitney U test. The number of events related to capillary glucose concentrations of less than 2·8 mmol/L and more than 20·0 mmol/L was tabulated in each 
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Results
Between Feb 20, 2015, and March 24, 2016, we recruited 40 participants, of whom 20 were randomly assigned to the closed-loop intervention and 20 to the control group (fi gure 1). One participant in the closed-loop group was withdrawn from the study because of acute gastrointestinal bleeding unrelated to study procedures, which required immediate surgical intervention and admission to the intensive care unit. Reasons for admission to hospital included infected foot ulcer (30 patients), ischaemic diabetic foot (four patients), congestive cardiac failure (four patients), and urinary tract infection (two patients). Table 1 summarises baseline characteristics (see appendix for details of pre-study treatment including the number of insulin injections per day). The insulin dose in the control group was adjusted by the general ward staff according to standard clinical practice; however, no additional injections or subcutaneous insulin sliding scale were given during the study.
The proportion of time spent in the target glucose concentration range (5·6-10·0 mmol/L) was higher in the closed-loop group than in the control group (59·8% [SD 18·7] vs 38·1% [16·7], respectively; diff erence 21·8% [95% CI 10·4-33·1]; p=0·0004; table 2). Mean sensor glucose concentration was lower, although not signifi cantly, in the closed-loop group than in the control group (p=0·065; table 2; fi gure 2). The proportion of time spent at concentrations greater than the target range (ie, >10·0 mmol/L) was signifi cantly lower in the closed-loop group than in the control group (diff erence 19·0% [95% CI 4·7-33·3]; p=0·011), whereas the time spent at concentrations lower than the target range (ie, <5·6 mmol/L) did not diff er between groups (p=0·51; table 2). Time spent at concentrations lower than 3·5 mmol/L and burden of hypoglycaemia as measured by area under the curve less than 3·5 mmol/L were low and similar between groups (table 2) . Five hypoglycaemic events were detected and notifi ed by low sensor glucose alarm in three patients receiving closed-loop insulin delivery. Oral carbohydrate treatment (20 g) was given during each event by the general ward staff , without the need for intravenous dextrose.
Glucose variability during closed-loop insulin delivery was signifi cantly reduced compared with conventional insulin therapy, as measured by the SD (p=0·007) and the coeffi cient of variation of sensor glucose concentration (p=0·042; table 2). Participants in the closed-loop group had higher overall time spent within the target range without a signifi cant increase in total daily insulin delivery (p=0·78). Glycaemic outcomes based on pre-meal and pre-bed capillary glucose concentrations did not diff er between study groups (table 3) .
The proportion of time when overnight (0000-0800 h) glucose was in the target range was signifi cantly higher in the closed-loop group than in the control group (diff erence 20·1% [95% CI 5·9-34·3]; p=0·007; table 4). The nocturnal burden of hypoglycaemia as measured by area under the curve less than 3·5 mmol/L did not diff er between groups (p=0·59). Glucose variability (0000-0800 h) and daytime (0800-0000 h) outcomes
See Online for appendix measured by the SD (p=0·030) and the between-night coeffi cient of variation of sensor glucose concentration (p=0·011) was reduced with closed-loop therapy compared with conventional therapy. Results from the daytime period (0800-0000 h; table 4) showed that the proportion of time spent in the target glucose concentration range was signifi cantly higher in the closed-loop group than in the control group (p=0·002). Daytime glucose variability, as measured by the SD of sensor glucose concentration (p=0·011) and the overall (p=0·039) and between-day (p=0·018) coeffi cient of variation of sensor glucose concentration, was reduced in the closed-loop group compared with the control group. We noted no signifi cant diff erences in mean sensor glucose concentration and area under the curve less than 3·5 mmol/L during the daytime period. Total time of sensor glucose availability was similar in the two groups (appendix). Glucose sensors were replaced seven times in the closed-loop group (fi ve because of sensor failures, two because of MRI scanning procedures) and three times in the control group (twice because of sensor failures, once because of MRI scanning procedure). The insulin pump device was removed on two occasions during the study because of MRI scanning procedures. No insulin pump failures occurred during the study.
No episodes of severe hypoglycaemia or hyperglycaemia with ketonaemia occurred in either group. One adverse event unrelated to study devices occurred in the closedloop group (gastrointestinal bleed). No serious adverse event occurred in either group. 17 (85%) of 20 participants in the closed-loop group stated that they were happy with their glucose concentrations in hospital during the study and 18 (90%) were happy to have their glucose concentrations controlled automatically by the closedloop system (fi gure 3). 19 (95%) would recommend the system to a friend or family member if they were admitted to hospital.
Discussion
Our results suggest that the use of a fully automated closed-loop insulin delivery system in patients with insulin-treated type 2 diabetes in the general ward is safe and feasible. Compared with the local hospital protocol for glucose management, time when sensor glucose concentration was in the target range was signifi cantly improved with the closed-loop delivery system, without increased risk of hypoglycaemia.
Professional societies' recommendations of target glucose concentrations in non-critical care settings (premeal blood glucose targets of <5·6 mmol/L, and random blood glucose concentrations of <10·0 mmol/L) are not currently attainable by many health-care institutions. 1, 15 These trends of suboptimal glucose control are seen even when speciality input is available. 16 In our study, time within the recommended target glucose range was increased by closed-loop insulin delivery by roughly 22% compared with a matched cohort receiving usual care. This outcome was achieved without an increase in the amount of insulin delivered, thereby further minimising the risk of hypoglycaemia. Although time spent in hypoglycaemia was similar in both groups, it was notably low in the control group. Avoidance and fear of hypoglycaemia is a primary concern of many health-care professionals caring for inpatients with diabetes, which might have contributed to this fi nding. Inpatient hypoglycaemia, either iatrogenic or disease-related, is associated with poorer outcomes such as increased morbidity and mortality. 17 The length of hospital stay is prolonged by hypoglycaemia, aff ecting overall health-care 
Worse than expected
What you expected Better than expected cost. 18 Several vulnerable populations in the general ward are known to be at an increased risk, such as older people (≥65 years) or individuals with poor nutritional intake. Severe hyperglycaemia with ketonaemia in potentially insulin-defi cient patients was mitigated by administration of basal insulin at 20% of pre-study insulin dose during the closed-loop intervention. The likelihood of ketonaemia in the studied population is inherently low, however, and we consider that regular administration of basal insulin injections might not be required in future studies.
Measures of sensor glucose variability during closedloop insulin delivery seem to be consistently reduced compared with during conventional insulin therapy. Glycaemic fl uctuations are known to occur in hospital inpatients as a result of nutritional status and intake, as well as changes in insulin sensitivity during the period of illness. The advantage of an automated-control, algorithm-directed insulin delivery system such as ours, compared with conventional insulin therapy, is the fi nely tuned frequent modulation of insulin delivery according to sensor glucose concentrations, thereby trading variability of insulin delivery with glycaemic consistency. Previous studies, predominantly in critical care settings, have reported a link between increased glucose variability and endothelial dysfunction 19 and mortality. 20 Our study was not statistically powered for these outcomes; thus, large, well designed studies are needed to establish whether reduction in glycaemic variability and improved glucose control by closed-loop insulin delivery, specifi cally in non-critical care settings, could have clinically meaningful and benefi cial eff ects.
Intravenous closed-loop insulin delivery systems have been studied in intensive care settings. [21] [22] [23] The need for intravascular access for insulin delivery in these studies limits use in the non-critical care general ward settings. A randomised study 24 was performed in hospitalised noncritical care type 2 diabetes patients, comparing standard glycaemic management with workfl ow-integrated algorithm for basal bolus insulin therapy, which ward staff accessed via a tablet device. Over a 7 day period, time in target range (3·9-10 mmol/L) and mean blood glucose levels were signifi cantly improved in the algorithm group. Patients in the algorithm group who applied blinded continuous glucose monitoring, however, had numerous hypoglycaemic events (sensor glucose <3·9 mmol/L) during the daytime. Post-hoc analysis suggests that higher lunchtime blood glucose which required higher correction insulin boluses may have been contributory. The aforementioned computerised glucose management system depends on ward staff input at meal times. Other novel strategies for inpatient glucose control include the use of GLP-1 and DPP-4 inhibitor based therapies, which are thought to have a lower risk of hypoglycaemia due to their glucose-dependent action. 25, 26 However adverse eff ect profi les such as nausea and vomiting may limit their use in hospital, especially in those with swallowing diffi culties and at increased risk of aspiration.
The strength of our study is the novel application of an automated closed-loop insulin delivery system in a realworld general ward environment. The closed-loop system used off -the-shelf devices including a commercially available subcutaneous real-time continuous glucose monitor and insulin pump, thereby reducing regulatory complexity and accelerating availability of the system for future clinical use. No prandial insulin delivery was administered, reducing the risk of hypoglycaemia caused by delayed or reduced meal consumption and skipped meals, while also reducing staff workload. In the control group, glucose control was managed according to local hospital guidelines refl ecting real-world practice in which wider use of basal-bolus insulin therapy in hospital as recommended by experts in the fi eld is not always feasible or safe.
Our study is limited by a single-centre setting, a short duration, and a predominance of patients with foot ulcers who were approached in view of their expected longer stay in hospital. Another potential limitation is the administration of daily basal insulin glargine in the closed-loop group, and not the control group, instigated during the initial study design phase to mitigate against potential ketonaemia in the event of prolonged pump disconnection. Because no historical data were available for the risk assessment before our study, this precaution was implemented until corroborative data related to closed-loop use in this unique population were available. Supportive fi ndings from the present work provide justifi cation to omit daily basal insulin glargine from future studies as a pragmatic measure to reduce staff workload without the need for a pilot study. The dose of basal insulin glargine given in our study, maintained at a constant dose throughout, is estimated to account for between 10% and 20% of the total (the sum of endogenous and exogenous) insulin concentration in type 2 diabetes, 21 thus negligible in terms of effi cacy in view of the adaptive nature of the closed-loop algorithm, which needs to cope with more than 30-times greater changes in insulin needs. Finally, the availability of low sensor glucose alarms in the closed-loop group might have potentially mitigated against hypo glycaemia events compared with the control group. Continuous glucose monitoring is currently not recom mended as part of usual clinical care in the general ward, while being an integral part of closed-loop systems. Therefore, low sensor glucose alarms in addition to automated modulation of insulin delivery based on realtime sensor glucose concentrations, could support the incremental benefi t of the closed-loop intervention in the general ward.
Although no formal feedback was collected from the ward staff , there was no interruption to the ward workfl ow and patients' usual ward-related activities from the closed-loop intervention. Patient feedback from closed-loop use suggests that the system acceptability was high, with most patients happy to have their glucose control managed autonomously by the closed-loop system, and suggest a substantial level of trust by patients. The absence of feedback from the control group limits interpretation on whether the closed-loop intervention improved patients' experience and perception of glucose control management in hospital.
In conclusion, our fi ndings show that automated closed-loop insulin delivery without meal-time boluses, or provision of information about meals to the control algorithm, in adults with insulin-treated type 2 diabetes is safe and feasible in the non-critical care setting. However, further and longer studies are warranted.
